Subject Index

A6 amphibian kidney cells, DEX and, 405
Acne, antiandrogens and, 59
Adaptable binding, 6
Adrenal weight stimulation test, drospirenone and, 319
Agonist/antagonist activities, 117
Agonists and antagonists, estrogen receptor and, 133
AIDS, glucocorticoid resistance syndromes and, 299
Anabolic/androgen test, drospirenone and, 317
Anabolic steroids, skeletal muscle injury and, 395
Androgen receptor (AR)
  conformation of, 351
  structure-activity correlations of, 17
Androgen receptor (AR) gene, synthetic oligonucleotides and, 97
Angiogenesis, VEGF and, 382
Antagonist design, summary of, 2
Antiandrogen, AR conformation and, 351
Antiandrogenic agent, 106
Antiestrogen
  breast cancer treatment and, 164
  pure, 176
    breast cancer and, 148
    tamoxifen and, 141
  types I and II, 109
Antiestrogen binding sites, 116
Antigene approach, 106
Antiglucocorticoid test (AGT), Org 33628 and, 195
Antigonadotropic effect, drospirenone and, 323
Antihormone, modes of action of, 5
Antimineralocorticoid and antiandrogenic effects, progesterone and, 311
Antiprogestagen, new selective, 192
Antiprogestins
  mechanism of action of, 202
  steroidal, 383
Antithymolytic effects, drospirenone and, 319
Antitumor activity, nonsteroidal pure antiestrogen and, 185
Antitumor agents, Org 33628 and, 198
AP-1, glucocorticoid receptor and, 262
Apoptosis, glucocorticoids in lymphoid cells and, 261
Athymic mice, tamoxifen and, 140

B16 mouse melanoma cells, GR in, 388
Basic fibroblast growth factor (bFGF), benign prostatic hyperplasia and, 74
Benign prostatic hyperplasia (BPH), sex steroids and EGF in, 66
Benzofuran, heterocycle and, 176
Benzothiophene, heterocycle and, 176
Binding, primary vs secondary, 116
Binding affinities, antiprogestagen, 195
Blood pressure, drospirenone and, 333
Blood-brain barrier, Casodex and, 87
Bone mineral density (BMD), raloxifene and, 360
Breast cancer
  clinical, pure estrogens in, 158
  early, mood disorder and, 365
  estrogen receptor and, 121
  heterocycle-based pure estrogen antagonists and, 176
  progesterone antagonists and, 225
  pure antiestrogens and, 149
  raloxifene and, 360
  RU 486 for, 257

C3H/HeJ endotoxin nonresponder mice, 280
Calcitriol, osteosarcoma cell growth retarded by, 349
Calcium channels, onapristone and, 213-215
Casodex, preclinical studies of, 79
Castration, medical, 79
Catatoxic steroids, liver metabolism in mice and, 278
CEM-C7 cells, human leukemic, 261
Cervical ripening, RU 486 and, 254
Cervix, uterine, effects of antiprogestins on, 215
Chromosome identification, localization of UR by, 41
Clinical applications, new era in, 3
Clones, CEM-C7 and related, 271
Competitive binding, type of, 6
Conformation, androgen receptor, 351
Conformation of hormone-receptor complex, 6
6-s-cis Conformation of 1α, 25-dihydroxyvitamin D_3, 344
Contraception, RU 486 for, 257
Core-binding site, nuclear hormone receptors and, 29
Cortisol-blocking agent, RU 486 as, 257
Cyclocymopol monomethyl ether, 383
Cyclophilin 40 (Cyp 40), 51

Cyproterone acetate (CPA)
antiandrogen effect of, 80
drospirenone and, 321
Cytokine production and toxicity, effect of RU 38486 on, 288

Demographic information, mood disorder in early breast cancer and, 366
Dermatologic diseases, antiandrogens and, 59
Dexamethasone (DEX), mineralocorticoid receptor and, 405
Diethylstilbestrol (DES), endocrine disturbances and, 369
Differentiation therapy, progesterone antagonists and, 224
1α, 25-Dihydroxyvitamin D_3, 6-s-cis conformation of, 344
Dopamine, estrogen receptor and, 123
Drospirenone, antiandrogenic and antimineralocorticoid activity of, 311
Drug design, aberrant hormone action and, 97
Drug resistance, tamoxifen and, 138

Ear, hamster, sebaceous gland of, 61
EB 1089, osteosarcoma cell growth retarded by, 349
Eker rat, spontaneous uterine leiomyomata in, 373
Endocrine evaluation, DES and, 369
Endocrine therapy, antiestrogens and, 159
Endometrial receptivity, effect of onapristone on, 207
Endometrial transformation, drospirenone and, 315
Endometriosis, RU 486 for, 257
Endotoxin lethality, liver function during, 277
Enzyme immunoassay, antiestrogens and, 111
Epidermal growth factor (EGF), benign prostatic hyperplasia and, 66
Epidermal growth factor receptor, effect of androgens on, 67
Epithelial differentiation, progesterone antagonists and, 236
Estradiol
antiestrogens and, 111
benzofuran derivatives and, 177
effect of, on uterus and vagina, 230
Estrogen antagonist, nuclear transport and, 361
Estrogen receptor (ER)
binding affinities for, 177
hormone- and antihormone-activated, 121
ICI 164384 and, 361
mutant, 141
raloxifene and, 355
structure-activity correlations of, 7
Estrogen response element (ERE), sequence of, 132
Estrogen-dependent functions, progesterone antagonists and, 227
Estrogen-regulated genes, 149
Estrogen-resistant breast cancer cell model systems, 153
Estrogenic activity
drospirenone and, 327
lack of or minimal, 184
Estrogens, benign prostatic hyperplasia and, 66

Feminization/virilization test, drospirenone and, 328
FKBP 12, 50
FKBP 59, 50
Flutamide
antiandrogen effect of, 81
benign prostatic hyperplasia and, 67
Forskolin
cell kill and, 270
steroid receptors and, 337
Future challenges, 1

Gap junctions, antiprogestins and, 211
Gemeprost, RU 486 and, 248
Gene transactivation, effect of UR expression on, 45
Glucocorticoid antagonist, RU 486 as, 301
Glucocorticoid hormones, stress and shock and, 276
Glucocorticoid receptor (GR)
cell death and, 261
DEX and, 405
GTT and, 391
HSP90 and, 403
mouse melanoma cells and, 388
RU 486 in man and, 296
structure-activity correlations of, 15
Glucocorticoid resistance, 299
Glucocorticoid sensitivity, 299
Glucocorticoids
leukemia and, 261
memory and, 400
Growth factors
estrogen receptor and, 125
overexpression of, RU 58668 and, 171
GTT, a Chinese traditional medicine, 391

Hard shell binding site, 6
Heat shock protein (HSP) 90
GR and, 403
immunosuppressants and steroids and, 50

Heat shock protein 90-binding immunophilin (HBI), 50
Hippocampus, glucocorticoids and, 400
Hoogsteen hydrogen bonding, 104
Hormone antagonist, definition of, 5
Hormone antagonists, summary of, 2
Hormone mechanism, summary of, 1
Hormones and antihormones, estrogen receptor and, 132
3β-Hydroxysteroid-dehydrogenase/5-ene-4-ene isomerase (3β-HSD), 193
4-Hydroxytamoxifen, antiestrogens and, 111
4-Hydroxytamoxifen, tamoxifen metabolized to, 139
Hypovolemic shock, GR and, 391

ICI 164384
  estrogen receptor signalling and, 155
  nuclear transport and, 361
ICI 182780
  estrogen receptor signalling and, 155
  tamoxifen-resistant tumors and, 176
Immediate early gene (IEG), skeletal muscle injury and, 395
Immunocytochemistry, localization of UR by, 41
Immunosuppressants, HSP 90 and, 50
Indole, 177
Induced-fit hypothesis, 6
Interference with hormone binding, 6
Interleukin 1 (IL-1), hemorrhagic shock and, 391
Intracellular receptor, specific, 123
Intrauterine fetal death (IUFD), RU 486 for, 252

Labor induction, RU 486 for, 256
Leiomyomas, uterine, 373
Libido, loss of, 79
Licorice-derived steroid analogs, 341
Lock and key model, 6
Luciferase, 17β-estradiol and, 181
LY 139481, estrogen receptor and, 355

Mammary carcinoma, RU 58668 and, 171
MCF-7 tumors, estradiol-stimulated, 164
MCF-7 variant, 165
MCF-7ras cell line, 165
Memory, glucocorticoids and, 400
Menstrual cycle, VEGF and, 382
Mifepristone (RU 38486), Org 33628 and, 192
Mineralocorticoid receptor, DEX and, 405
Misoprostol, RU 486 and, 248
MMTV transcription, increase in, 53
Mood disorder, early breast cancer and, 365
MTT assay, 264
myc mRNA, GR-positive, lysis-resistant clone CEM C1 and, 265
Myometrium, effects of antiprogestins in, 211

Natriuretic effect, drospirenone and, 334
Nilutamide, antiandrogen effect of, 81
Nitric oxide system, antiprogestins and, 215
Northern blot analysis, RU 486 in CEM-C7 cells and, 263
Nuclear factor κB (NF-κB), antiandrogen action of, 98, 106
Nuclear hormone receptors
  definition of, 29
  evolutionary relationship of, 40
Nuclear transport, ICI 164384 and, 361

Oligonucleotide inhibitor, synthetic, 98
Onapristone (ZK 98299)
  effect of, on uterus and vagina, 230
  mechanisms of action of, 203
  Org 33628 and, 192
Oncogenes, 266
  overexpression of, RU 58668 and, 171
Orchidectomy, Casodex and, 79
Org 33628, pharmacological properties of, 192
Orphan receptor, isolation of, 38
Osteoarthritis, 299
Ovulation, drospirenone and, 321
Oxytocin receptor, antiprogestins and, 211

Parturition, effects of antiprogestins on, 208
Periimplantation period, effect of antiprogestins during, 206
Peripherally selective antiandrogen, Casodex and, 85
Pharmacological profile, drospirenone, 333
Phosphorothioate derivative, 104
Pregnancy
  advanced, effects of antiprogestins during, 207
  maintenance of, drospirenone and, 317
Pregnancy interruption test (PIT), Org 33628 and, 195
Pregnancy termination, RU 486 and, 248
Primate uterus, VEGF in, 376
Progesterone
  antiandrogenic and antimineralocorticoid activity of, 311
  functions of, during pregnancy, 203
Progesterone antagonists, differentiation therapy with, 224
Progesterone receptor (PR)
  breast cancer and, 121
  human, 383
  structure-activity correlations of, 13
Prolactin (PRL), DES and, 369

Promoter, estrogen receptor agonists and, 127
Prostaglandin E1, RU 486 and, 248
Prostaglandins, uterine, effects of antiprogestins on, 209
Prostate cancer, progesterone antagonists and, 225
Prostate tumor cell, effect of Casodex on, 83
Protein kinase A, glucocorticoid receptor and, 268
Provitamin D skeleton, 1α,25-dihydroxyvitamin D_3 and, 344

Raloxifene, estrogen receptor and, 355
Rat androgen receptor (rAR) promoter, 97
Receptor abnormalities and hormone resistance, 2
Receptor binding, drospirenone and, 319
Response element, composition of, 29
9-cis Retinoic acid, DNA binding properties of, 29
all-trans Retinoic acid, DNA binding properties of, 29
Retinoic acid receptor, ubiquitous receptor and, 47
Rheumatoid arthritis, glucocorticoid resistance syndromes and, 299
RU 38486 (mifepristone)
  AR conformation and, 351
  clinical uses of, 248
  endotoxicosis and, 280
  glucocorticoid resistance syndromes and, 299
  hemorrhagic shock and, 391
  mechanisms of action of, 203
  pharmacokinetics of, 301
  VEGF and, 382
RU 58668
  antiestrogens and, 111
  breast cancer treatment and, 164
RU 58841, sebaceous gland growth and, 56
RXR, ubiquitous receptor competition with, 46

Sebaceous gland, RU 58841 and, 56
Second-term pregnancy termination, RU 486 and, 252
Sedimentation peaks, estradiol and 4-hydroxytamoxifen levels and, 112
Septic shock, influence of RU 38486 on, 282
Sex organs, accessory, effect of Casodex on, 91
Sexual differentiation, drospirenone and, 331
Shock, glucocorticoid hormones and, 276
Side effects, antiandrogens and, 59
Signal transduction pathways, estrogen receptor and, 123
Species differences, antiandrogens and, 60
Spironolactone, drospirenone and, 332
Steroid dehydrogenases, licorice-derived steroid analogs and, 341
Steroid hormone antagonists, summary and future challenges of, 1
Steroid hormone receptor, mechanism of action of, 123
Steroid receptor
  benign prostatic hyperplasia and, 68
  binding affinities to, 195
  forskolin and, 336
Steroid receptor function, licorice-derived steroid analogs and, 341
Steroid-hormone action, different steps in, 6
Steroid-resistant asthma, 299
Stress
  glucocorticoid hormones and, 276
  GR and, 391
Structure-activity correlations of antihormones, 7
Sulprostone, RU 486 and, 250

Tamoxifen
  drug resistance to, 138
  escape from, 165
  ICI 164384 and ICI 182780 vs, 152
  ICI 182780 and, 176
  mood disorder and, 365
  uterine myometrial cells and, 374
Tamoxifen-resistant cells, 155
Thyroid hormone, DNA binding properties of, 29
Thyroid hormone receptor, ubiquitous receptor competition with, 46
Topical antiandrogens, 60
Trans-activating function-1 (TAF1), 127
Transactivation assays
  drospirenone and, 313
  progesterone antagonists and, 232
Transcription, pure antagonist and, 181
Transcription assays, progesterone antagonists and, 230
Transcription factors, glucocorticoid receptor and, 262
Transcription machinery, cellular, 127
Transfection, luciferase activity and, 181
Transforming growth factor β (TGFβ), benign prostatic hyperplasia and, 75
Triple helix-forming oligonucleotides (TFOs), 102, 104
Tumor necrosis factor α (TNF-α), endotoxin-induced shock and, 288
Two-site model, 117

Ubiquitous receptor (UR), discovery of, 39
Ubiquitous receptor heterodimerization, 45

Uterine epithelium, raloxifene and, 360
Uterus, antiprogestins in, 202

Vascular endothelial growth factor (VEGF), primate uterus and, 376
Vitamin D_3, binding properties of, 29

Wasting syndrome, RU 38486 and, 286
Wild type estrogen receptor (ER-wt), 127

ZM 164384 and ZM 182780, antiestrogens and, 111
Zoladex, prostate cancer and, 79

Index of Contributors

Abu-Shakra, S. R., 395-399
Agarwal, M. K., 276-295
Akil, H., 403-404
Assies, J., 369-372

Bamberger, C. M., 296-310
Baulieu, E-E., 50-55
Bender, S. L., 383-387
Biberger, C., 176-191
Bleker, O., 369-372
Bouchoux, F., 5-28
Brémaud, J., 164-175
Bryant, H. U., 355-360
Bukowski, R., 376-382

Caamaño, C. A., 403-404
Catherino, W. H., 138-147
Cérède, E., 5-28
Chatterjee, B., 97-108
Chen, S., 97-108
Chrousos, G. P., 296-310
Chwalisz, K., 202-223
Cole, H. W., 355-360
Cumming, D. C., 365-368
Cumming, C. E., 365-368

Dalman, F. C., 403-404
Dana, S. L., 121-137
Davtian, A., 383-387
de Gooyer, M. E., 192-201
Deckers, G. H., 192-201
Dijkema, R., 192-201
Djordjević-Marković, R., 388-390
Dormanen, M. C., 344-348
Draper, M. W., 355-360
Duax, W. L., 341-343
Duda, E., 276-295

Einspanier, A., 202-223
Erman, M., 341-343
Evans, R. M., 29-37
Everitt, J. I., 373-375

Farmer, L. J., 383-387
Forman, B. M., 29-37
Fritzemeier, K. H., 202-223, 311-335
Fuchs-Young, R., 355-360
Fuhrmann, U., 202-223, 311-335
Furr, B. J. A., 79-96

Gaillard, M., 56-65
Garfield, R. E., 202-223
Gee, J. M. W., 148-163
Ghosh, D., 341-343
Glasebrook, A. L., 355-360
Gofflo, D., 5-28
Goldman, M. E., 383-387
Gong, X. Q., 391-394
Goodman, A. L., 376-382
Gottardis, M. M., 373-375
Greb, R. R., 376-382

Hagley, R. D., 405-407
Hamann, L. G., 383-387
Hameau, M-C., 164-175
Hammond, M. W., 344-348
Handman, M., 365-368
Hedden, A., 109-120
Henderson, D., xi
Hiipakka, R. A., 38-49
Hodgen, G. D., 376-382
Hoener, P. A., 121-137
Hoversten, M. T., 403-404
Howe, S. R., 373-375
Hsiu, J. G., 376-382
Husztik, E., 276-295

Imhof, M. O., 121-137
Isenović, E., 336-340

Jääskeläinen, T., 349-350
Jacobson, M. W., 400-402
Jensen, E. V., 1-4, 109-120
Johnson, B. H., 261-275
Johnson, M. G., 383-387
Jones, T. K., 383-387
Jordan, V. C., 138-147
Jung, M. H., 97-108

Kanazir, D. T., 336-340, 388-390
Katzenellenbogen, B. S., 148-163
Keenan, P. A., 400-402
Kloosterboer, H. J., 192-201
Kokontis, J. M., 38-49
Krattenmacher, R., 311-335
Kuil, C. W., 351-354

Labrie, F., 341-343
Lázár, G., 276-295
Lázár, G., Jr., 276-295
Lee, C., 361-364
Lees, A., 365-368
Leichtl, S., 176-191
Lemoine, G., 5-28
Liao, S., 38-49
Lieberman, B. A., 121-137

Lin, C. Q., 391-394
Lin, S-X., 341-343
Lu, J. H., 391-394
Lumey, L., 369-372

Mäenpää, P. H., 349-350
Magee, D. E., 355-360
Mahonen, A., 349-350
Mais, D. E., 383-387
Manning, D. L., 148-163
Matias, J. R., 56-65
McDonnell, D. P., 121-137
Michna, H., 224-247
Midland, M. M., 344-348
Miksicek, R. J., 361-364
Montano, M. M., 148-163
Morano, M. I., 403-404
Muhn, P., 311-335
Mulder, E., 351-354
Müller, V., 109-120

Nachtman, F. C., 395-399
Neff, S., 361-364
Nemere, I., 344-348
Newcomer, J. W., 400-402
Nicholson, R. I., 148-163
Nique, F., 5-28, 164-175
Nishino, Y., 224-247
Norman, A. W., 344-348

Okamura, W. H., 344-348
Orlemans, E. O. M., 192-201

Pangborn, W., 341-343
Parczyk, K., 224-247
Peyron, R., 248-260
Philibert, D., xi, 5-28, 164-175
Pletnev, V., 341-343
Pratt, W. B., 403-404

Radojčić, M., 388-390
Ribarac-Stepić, N., 336-340, 388-390
Rippy, M. K., 355-360
Ristić-Fira, A., 388-390
Roy, A. K., xi, 97-108

Saeed, M. F., 261-275
Schillinger, E., 311-335
Schneider, M. R., 224-247
Schoonen, W. G. E. J., 192-201
Sciarra, F., 66-78
Shariff, S., 365-368
Shi, H. P., 391-394
Short, L. L., 355-360
Silvestre, L., 248-260
Soleymani, R. M., 400-402
Song, C. S., 97-108
Song, Ching, 38-49
Stein, R. B., 121-137
Stöckemann, K., 202-223
Supakar, P. C., 97-108

Termine, J. D., 355-360
Teutsch, G., xi, 5-28, 164-175
Thompson, E. B., 261-275
Thulasi, R., 261-275
Topp-Rapiejko, K., 361-364

Ulmann, A., 248-260

Van de Velde, P., 164-175
Vellanoweth, R. L., 97-108
Von Angerer, E., 176-191
Vonk, J., 369-372

Wakeling, A. E., 148-163
Walker, C., 373-375
Watlington, C. O., 405-407
Watson, S. J., 403-404
Wawrzak, Z., 341-343
Williams, R. F., 376-382
Wolf, D. M., 138-147
Wu, J., 391-394

Xu, R-B., 391-394

Žakula, Z., 336-340
Zhu, D-W., 341-343